A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). [electronic resource]
Producer: 19990618Description: 99-104 p. digitalISSN:- 0306-5251
- Bezafibrate -- adverse effects
- Cohort Studies
- Comorbidity
- Diabetes Complications
- Female
- Gemfibrozil -- adverse effects
- Humans
- Hypertension -- complications
- Lipids -- blood
- Male
- Myocardial Ischemia -- prevention & control
- New Zealand
- Practice Patterns, Physicians'
- Product Surveillance, Postmarketing -- methods
- Random Allocation
- Retrospective Studies
- Risk Factors
- Simvastatin -- adverse effects
- Surveys and Questionnaires
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.